Segn especialistas que han comenzado a utilizar la molcula, ms del 90% de los pacientes presenta una respuesta metablica favorable desde la dosis mnima, lo que permite una estrategia teraputica progresiva y sostenida
Grady RW, Galanello R, Randolph RE, Kleinert D, Dessi C, Giardina PJ
The update will indicate whether the plaintiffs intend to pursue a preliminary injunction against the FDA
If more than 48 hours have passed, skip the missed dose
Adverse Effects from GLP-1 Therapeutic Use, Dosing Errors, & Overdose GLP-1 agonists often cause gastrointestinal side effects, occurring in up to 50% of patients in some instances
However, there is still a significant difference between the WL that can be achieved with bariatric surgery and the currently approved obesity pharmacotherapies and there is heterogeneity in treatment responses with GLP-1 RA (for example people with T2D may achieve less WL compared to those without diabetes in clinical trials, despite similar lifestyle interventions) [13, 14]